Search Results
Your search for The,The matches 34082 pages
Showing 351 - 400Large Proportion of Childhood Cancer Survivors May Experience Significant Fear of Cancer Recurrence
Investigators have found that one-third of adult survivors of childhood cancers may experience a severe fear of cancer recurrence that impacts their daily lives, according to a recent study published by Pizzo et al in JAMA Network Open. Background Although the number of survivors of childhood...
New Data From SWOG S1826 Trial May Confirm Benefit of Nivolumab Plus AVD in Patients With Hodgkin Lymphoma
Researchers have found that the combination of nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) may reduce the risk of cancer progression and mortality in patients with Hodgkin lymphoma compared with standard treatment, according to a recent study published by Herrera et al in The New ...
Association of TERT Expression and Survival in Pulmonary Carcinoids
As reported in the Journal of Clinical Oncology by Werr et al, high telomerase reverse transcriptase (TERT) expression has been found to be associated with poorer survival in patients with pulmonary carcinoids. As stated by the investigators: “The clinical course of pulmonary carcinoids ranges from ...
Addition of Thoracic Radiotherapy to First-Line Treatment of EGFR-Mutated Metastatic NSCLC
In a Chinese phase III trial (Northern Radiation Oncology Group of China-002) reported in the Journal of Clinical Oncology, Sun et al found that the addition of thoracic radiotherapy to EGFR tyrosine kinase inhibitor (TKI) treatment improved progression-free survival in first-line treatment of...
Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC
On October 15, 2024, Novocure announced the U.S. Food and Drug Administration (FDA) approval of Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) who have experienced disease progression on or after...
Addition of Ramucirumab to Osimertinib in TKI-Naive EGFR-Mutant Metastatic NSCLC
In an interim analysis of the phase II RAMOSE trial, reported in the Jour�nal of Clinical Oncology, Le et al found that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival as initial treatment in patients with tyrosine kinase inhibitor (TKI)-naive...
Standard vs Extended Lymphadenectomy in Radical Cystectomy for Muscle-Invasive Bladder Cancer
As reported in The New England Journal of Medicine by Lerner et al, the phase III SWOG S1011 trial showed no disease-free survival benefit for extended vs standard lymphadenectomy in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Study Details In the trial, 592 patients ...
Head and Neck Cancer Clinical Trials May Be Becoming Less Diverse, Despite National Efforts
Many patients with head and neck cancer may lack equal opportunity to access experimental treatments in clinical trials or receive treatments that were shown to be effective in similar patients, according to a recent study published by Zuckerman and Edwards in Head & Neck. Background Millions...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Cancer Clinical Trials May Continue to Be Inaccessible for Many Patients
Millions of U.S. patients with cancer may face barriers to accessing some of the most advanced treatments being tested in clinical trials for their disease, according to a recent study published by Kirkwood et al in JCO Oncology Practice. Background “We need to support bringing clinical trials to...
Patients With Multiple Sclerosis May Have an Increased Risk of Certain Types of Cancer
Some cancer types may be slightly more prevalent among patients with multiple sclerosis compared with those without the condition, according to a recent study published by Pierret et al in Neurology. Background In multiple sclerosis, the body’s immune system attacks myelin, the fatty white...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
Capmatinib in MET Exon 14–Mutated NSCLC
As reported in The Lancet Oncology by Wolf et al, the final results of the phase II GEOMETRY mono-1 trial support the activity of the kinase inhibitor capmatinib in patients with non–small cell lung cancer (NSCLC) with MET exon 14–skipping mutation (METex14). Study Details The multicohort trial...
Association of Excess Body Weight and Risk of Second Primary Cancers Among Survivors of First Primary Cancers
In a study reported in JAMA Network Open, Bodelon et al found that survivors of first primary cancers with overweight or obesity were at increased risk for second primary cancers, particularly obesity-related cancers. Study Details The study focused on data from the Cancer Prevention Study II...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1...
Updated Findings in Prostate Cancer Screening With Systemic Biopsy vs MRI-Targeted Biopsy
Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic resonance imaging (MRI) results eliminated a high proportion of diagnoses of clinically insignificant...
Radiation-Associated Secondary Cancers in Breast Cancer Harboring TP53 Germline Pathogenic Variants
In a study published as a research letter in JAMA Oncology, Cederquist et al found that patients with breast cancer who received adjuvant radiation therapy and harbored likely pathogenic TP53 germline variants were at increased risk of developing secondary in-field sarcoma during follow-up. Study...
New Directions in ALL, CML, and CLL Treatment
The Society of Hematologic Oncology (SOHO) 2024 Annual Meeting showcased several groundbreaking studies in the field of hematologic oncology, including key findings in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). The ASCO...
African Men May Have Higher Risk of Developing Prostate Cancer Earlier
Researchers have identified genetic risk factors that may contribute to prostate cancer in a diverse group of African men, according to a recent study published by Janivara et al in Nature Genetics. The findings could uncover new treatment options in this patient population. Background Certain...
Higher Dosage of Radioembolization With Y-90 Therapy May Improve Survival Rates and Facilitate Curative Treatment in Patients With Hepatocellular Carcinoma
Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing....
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters
The nation’s intravenous fluid shortage was exacerbated this week when flooding from Hurricane Helene damaged a Baxter International plant in North Cove, North Carolina, which makes about 60% of the United States’ supply of fluids used in IVs for patients with a variety of diseases, including...
Sintilimab/Bevacizumab in Relapsed or Persistent Ovarian Clear Cell Carcinoma
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma. Study Details In the multicenter trial, 37 evaluable patients with exposure...
FDA Approves Inavolisib Combination in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) approved the PI3K inhibitor inavolisib (Itovebi) with the CDK4/6 inhibitor palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, as...
Global Disparities May Exist in Availability, Timeliness of New Cancer Drugs
Despite considerable progress in the discovery and development of new cancer drugs between 1990 and 2022, there may be disparities in both the availability and timeliness of these treatment options globally, particularly among lower-income countries, according to a recent study published by Li et...
Two Universities to Develop Incisionless Prostate Cancer Surgery Using MRI and Robotics
Researchers at Case Western Reserve University and Vanderbilt University have received a $3.7 million grant from the National Cancer Institute to pioneer a novel approach to prostate cancer surgery that combines advanced robotics and low-field magnetic resonance imaging (MRI) technology. Overview...
Bridging the Gap in Cancer Clinical Trial Funding
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, responded to a recent study by the Fred Hutchinson Cancer Center in Seattle that found enrollment in industry-sponsored cancer clinical trials doubled between 2008 and 2022, whereas federally supported trial...
Can Blood Test Predict Survival in Metastatic Prostate Cancer?
A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...
One-Dose HPV Vaccination Approach May Help to Eliminate Cervical Cancer
Canadian vaccination programs may switch to a one-dose, gender-neutral human papillomavirus (HPV) vaccination approach to eliminate cervical cancer, according to a recent study published by Drolet et al in the Canadian Medical Association Journal. Background HPV is known to cause cervical cancer...
Novel Cell Therapy May Offer Benefit in Patients With Relapsed or Refractory T-Cell ALL
A novel cell therapy targeting CD7 on leukemia cells may provide an effective treatment option for patients with refractory T-cell acute lymphoblastic leukemia (ALL), according to a recent study published by Oh et al in Nature Medicine. The findings highlighted the effectiveness of a new chimeric...
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I NSCLC
As reported in JAMA Oncology by Swaminath et al, the Canadian phase III LUSTRE trial has shown no significant benefit in local tumor control with stereotactic body radiotherapy (SBRT) vs hypofractionated conventional radiotherapy (CRT) in patients with inoperable stage I non–small cell lung cancer...
Exercise Linked to Fewer Falls in Older Adults With Cancer
A recent study suggests that for people older than age 65 who have cancer, physical activity may be key to reducing the chances of a dangerous fall. People with lung cancer, colorectal cancer, or prostate cancer, in particular, had a lower risk of falling when they talked with their doctor...
Transperineal vs Transrectal Prostate Biopsy for Suspicion of Prostate Cancer
In the PREVENT trial, reported as a research letter in JAMA Oncology, Hu et al found that transperineal prostate biopsy resulted in less risk of infection than transrectal biopsy in patients with suspicion of prostate cancer, with no difference between methods observed in detecting high-grade...
Sexual Health and Quality of Life With Simple vs Radical Hysterectomy in Low-Risk, Early-Stage Cervical Cancer
In an analysis from the phase III SHAPE trial reported in the Journal of Clinical Oncology, Ferguson et al found that simple hysterectomy was associated with a reduced risk of sexual dysfunction vs radical hysterectomy in patients with low-risk, early-stage cervical cancer. The trial showed...
Common Breast Cancer Treatments May Speed Aging Process
Researchers have found that common breast cancer treatments—including chemotherapy, radiation, and surgery—may accelerate the biological aging process among breast cancer survivors, according to a new study published by Carroll et al in the Journal of the National Cancer Institute. The findings...
ACA’s Dependent Coverage Expansion May Have Benefited Young Adult Patients Diagnosed With Cancer
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer. The federal...
Addition of Liver Transplantation to Chemotherapy for Permanently Unresectable Colorectal Cancer Liver Metastases
In the European TransMet trial, reported in The Lancet, Adam et al found that liver transplantation plus chemotherapy improved overall survival vs chemotherapy alone in patients with permanently unresectable colorectal cancer liver metastases. Study Details In the open-label trial, 94 patients...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
Coping With the Risk of Hereditary Cancer
Three years ago, it had become clear that I needed to be tested for the BRCA1/2 mutation. I knew my family history of cancer was not good. My paternal grandmother died of breast cancer when she was just 41, and her mother had likely died of cervical cancer when she was in her 50s. More recently,...
Ann Partridge, MD, MPH, Receives ESMO Award for Significant Contributions to Breast Cancer Research and Patient Care
Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, was named the recipient of the 2024 ESMO Award during the opening session of the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The international award recognizes her work and commitment to the field of breast...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
Cancer Provider Groups Across the Country Urge Congress to Pass Prior Authorization Reform
The Association for Clinical Oncology (ASCO), along with 46 state oncology societies, sent a letter to U.S. House and Senate leadership urging Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 8702/S. 4532), which would streamline prior authorization practices within Medicare...
ASHP Offers New Guidance for Managing IV Fluid Shortages
The American Society for Health-System Pharmacists (ASHP) and the University of Utah announced updated recommendations for managing intravenous fluid shortages and conserving supply after Hurricane Helene forced the closure of a critical manufacturing plant in North Carolina. The management and...
ASCO Updates Stage III NSCLC Guideline to Include Osimertinib in Wake of LAURA Trial Data
ASCO has issued a rapid update to its guideline on the management of stage III non–small cell lung cancer (NSCLC), based on the results of the phase III LAURA trial, which was presented at the 2024 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.1,2 The...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
ChatGPT May Demonstrate Human-Level Assessment of Brain Tumor MRI Reports
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
